iBET publication “Patient-derived ovarian cancer explants: preserved viability and histopathological features in long-term agitation-based cultures” is featured in EATRIS 2020 Annual Report, a high-level overview of 2020 EATRIS activities and highlights representing the “energy, dedication and expertise of the EATRIS community”.
This research is the product of a successful collaboration with AbbVie and IPOLisboa and describes the development of a long-term ovarian carcinoma patient-derived explant (OvC-PDE) retaining the original architecture and cell type heterogeneity of the primary tumour.
One of the main therapeutic challenges related with ovarian carcinoma is the tendency to develop resistance after initial response to chemotherapy. Explants developed in this study harbour the potential to study drug response and resistance mechanisms contributing for the development of novel precision medicine approaches.
Congratulations to the authors Sofia Abreu, Fernanda Silva, Rita Mendes, Teresa F. Mendes, Marta Teixeira, Vítor Espírito Santo, Erwin Boghaert, Ana Felix and Catarina Brito.
EATRIS – European infrastructure for translation medicine – currently comprises over 80 leading European academic institutions, selected on the basis of their track record in public-private collaboration in the translational development, multidisciplinary teams of leading academic experts and high-end research facilities and licenses. Within the infrastructure, iBET is part of the ATMP and Vaccines platforms.
Learn more about EATRIS network and its contribution for translational research: https://eatris.eu/eatris-2020-annual-report/